Clinical trials: Schizo-affective Disorder
Schizophrenia, Schizophreniform Disorder
rTMS in First Episode Psychosis
This study proposes to examine the application of rTMS for the treatment of cognitive dysfunction in FEP. This is an important population for study because if effective, rTMS may represent a preventative treatment for the…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- EmeraldThunder (NCT02131129)
- Testing
- rTMS
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Schizophrenia, Schizo Affective Disorder
Targeting Auditory Hallucinations With Alternating Current Stimulation
Investigating the effects of non-invasive transcranial alternating current stimulation (tACS) as a treatment for auditory hallucinations in patients with schizophrenia.
- Trial name
- STILL3 (NCT03221270)
- Testing
- tACS treatment week, Maintenance tACS
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Schizo-affective Disorder
Effects of Metformin and Fish Oil on Treatment With Clozapine
One purpose of this study is to test whether adding metformin will limit some of the unwanted effects of clozapine, compared to not adding metformin.
- Trial name
- NCT02140788
- Testing
- Metformin, Fish Oil
- Volunteers
- 34 people
- Sponsor
- Duke University
Schizophrenia, Schizoaffective Disorder
Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia
This is a 24-week, randomized, double-blind, placebo-controlled trial of exenatide weekly injection (2mg per dose) as an adjunctive therapy in 70 schizophrenia subjects to examine exenatide's effects on negative symptoms and…
- Trial name
- NCT02417142
- Testing
- Exenatide
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Massachusetts, Worcester
Schizophrenia, Schizoaffective Disorder
Mindfulness Meditation as a Rehabilitation Strategy for Persons With Schizophrenia
The purpose of this study is to develop a treatment manual for mindfulness meditation to be taught in a group format to individuals with schizophrenia who are engaged in vocational rehabilitation.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
- Trial name
- NCT00936351
- Testing
- Mindfulness Meditation, Support Group (control)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia
Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis
This 52 week long study evaluates the effectiveness of aripiprazole versus risperidone in treating people with first-episode schizophrenia.
- Trial name
- NCT00320671
- Testing
- Aripiprazole, Risperidone
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- Northwell Health
Schizophrenia, Schizoaffective Disorder
Motivational Negative Symptoms in Schizophrenia: Intervention and Biomarkers
Negative symptoms significantly interfere with daily functioning among individuals with schizophrenia. They are strongly related to functional impairments [1] and contribute to the poor community outcomes of Veterans with…
- Trial name
- NCT02386605
- Testing
- Motivational Interviewing and Cognitive Behavioral Therapy, Relaxation Skills
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder, Depressive Type
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Depressive Type, Schizophreniform Disorder
- Trial name
- APPRAISE (NCT04203056)
- Testing
- Aripiprazole Lauroxil, ARI-ORAL, AL-NCD
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Los Angeles
Schizophrenia, Schizophreniform Disorder
Omega-3 Dietary Supplements in Schizophrenia
This 16-week placebo-control study looks to investigate whether patients with schizophrenia for two years or less may benefit from omega-3 supplements.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT01786239
- Testing
- Risperidone, Omega-3 capsules
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Delbert Robinson
Schizophrenia, Schizoaffective Disorder
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
Treatment of schizophrenia currently includes antipsychotic medications and cognitive therapies which improve some symptoms, but do not sufficiently restore cognitive functioning or reduce psychosocial disability.
- Trial name
- NCT04857983
- Testing
- Memantine
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of California, San Diego
Schizophrenia, Schizoaffective Disorder
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Varenicline (Chantix) is a smoking cessation treatment that was approved in 2006 by the FDA for treatment of nicotine dependence and may be particularly beneficial in smokers with schizophrenia or bipolar disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Smoking
- Trial name
- SCRP (NCT00621777)
- Testing
- Varenicline
- Where
- 10 sites in United States
- Volunteers
- 247 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizoaffective Disorder
Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to establish pharmacodynamics (PD), pharmacokinetics (PK), and adverse event (AE) profile of OPC-34712 administered to schizophrenic/schizoaffective subjects.
- Trial name
- NCT01423916
- Testing
- OPC-34712 (4mg), Moxifloxacin, OPC-34712 (12mg)
- Where
- 8 sites in United States
- Volunteers
- 218 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder
This study will assess whether olanzapine and/or risperidone affect the way the human body uses sugar in the blood.
- Trial name
- NCT00190749
- Testing
- olanzapine, risperidone
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia
The study looks at whether treatment with iloperidone (Fanapt) is associated with improvements in social cognition in individuals who have been recently diagnosed with schizophrenia or schizoaffective disorder.
- Trial name
- NCT01929889
- Testing
- Iloperidone
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Northwestern University
Schizophrenia, Schizoaffective Disorder
Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia
Investigating the effect of non-invasive transcranial current stimulation on auditory hallucinations in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Auditory Hallucinations
- Trial name
- NCT01963676
- Testing
- tDCS
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Bipolar Disorder
Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis
The purpose of this study is to better understand mental illness and will test the hypotheses that, while viewing affective stimuli, patient groups will show increased blood oxygenation level dependent (BOLD) signal by fMRI after…
- Conditions
- Schizophrenia, Bipolar Disorder, Healthy, Psychosis
- Trial name
- GABAmech (NCT04004416)
- Testing
- Lorazepam and fMRI
- Where
- United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Schizophrenia, Dual Diagnosis
Cannabis and Schizophrenia: Self-Medication and Agonist Treatment
The first aim of this study is to determine whether a brain reward center (BRC) deficiency in patients with schizophrenia (SCZ) and cannabis use disorder (CUD) will be normalized when patients are given cannabis or dronabinol.
- Conditions
- Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder
- Trial name
- NCT00946348
- Testing
- Dronabinol, Cannabis
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Bipolar Disorder, Schizophrenia
Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders
Persons with serious mental illness (SMI) are at increased risk of cardiovascular disease (CVD). The goals of this study are to test a treatment, Life Goals Collaborative Care to help promote health behavior change and improve…
- Conditions
- Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Schizoaffective Disorder
- Trial name
- NCT01487668
- Testing
- Life Goals Collaborative Care
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- VA Office of Research and Development